Science Daily -
16 Apr 2021 20:01
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study. MK-4482, delivered orally, is now in human clinical trials.
Share this Article